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ABSTRACT
The case of an elderly man with an advanced oropharyngeal cancer that was missed during esophagogastroduodenoscopy is described. He 
was referred for endoscopic resection of superficial esophageal squamous cell neoplasms. He died a month after referral due to an advanced 
oropharyngeal cancer with a metastatic lesion to the brain. Patients with esophageal squamous cell carcinoma are high risk for head and 
neck cancer. The pharynx is the most common site for cancer in the head and neck region. Consequently, the pharynx should be observed 
carefully when patients with esophageal squamous cell carcinoma undergo esophagogastroduodenoscopy.
LEARNING POINTS
•  Head and neck cancer develops in approximately 10% of patients with esophageal squamous cell carcinoma.
•  The pharynx should be observed carefully when patients with esophageal squamous cell carcinoma undergo esophagogastroduodenoscopy 
because the pharynx is the most common site for cancer in the head and neck region.
•  Sedation using narcotic drugs can reduce the gag reflex but still allow patients to vocalize and offer adequate conditions for pharyngeal 
observation during esophagogastroduodenoscopy.
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CASE DESCRIPTION
Two years prior to his current presentation, a man in his 70s underwent esophagogastroduodenoscopy (EGD) which resulted in the 
detection of two superficial esophageal squamous cell neoplasms. However, as he declined treatment, follow-up EGDs were performed 
every 6 months. The lesions gradually spread laterally. He finally requested treatment for the esophageal neoplasms and was referred to 
hospital for endoscopic resection. An EGD performed 3 weeks after his previous EGD revealed an advanced oropharyngeal cancer in the 
right glossotonsillar sulcus (Fig. 1, 2). He was referred to an otorhinolaryngologist for further investigation. Computed tomography revealed 
a metastatic lesion to the brain. 
He received palliative care and died a month after referral to hospital.
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Figure 1. Esophagogastroduodenoscopy performed three weeks after patient’s 
last esophagogastroduodenoscopy showing the normal uvula at the center but 
irregularity on the right lateral wall of the oropharynx
Figure 2. Esophagogastroduodenoscopy showing an advanced oropharyngeal 
cancer in the right glossotonsillar sulcus
DISCUSSION
Patients with esophageal squamous cell carcinoma are at high risk for second primary cancers. Head and neck cancer is one of the most 
common double cancers and develops in approximately 10% of patients with esophageal squamous cell carcinoma[1,2]. 
The concept of field cancerization has been implicated in the pathogenesis of second primary head and neck cancer[3]. The pharynx is the 
most common site for cancer in the head and neck region, and pharyngeal cancer sometimes progresses to an advanced stage without 
symptoms. Therefore, the pharynx should be observed carefully when patients with esophageal squamous cell carcinoma undergo EGD.
Endoscopic screening method for the head and neck region has not been standardized including in Japan where endoscopists are more 
interested in the head and neck region than in most countries. Except for esophagus specialists, most endoscopists are still unfamiliar with 
monitoring the pharynx because they consider the pharynx to be the field of otorhinolaryngologists. Indeed, some endoscopists do not 
observe the pharynx at all. Therefore, even advanced oropharyngeal cancers such as the present case can be easily missed during EGD. 
Patient vocalization during pharyngeal observation can facilitate observation of pharyngeal area whereas the gag reflex usually obscures 
an endoscopic view. To reduce the gag reflex, sedation with benzodiazepines or propofol is often performed during EGD. However, it usually 
prevents patients from vocalizing and obscures an endoscopic view of the pharynx, contrary to expectation.
Sedation with narcotic drugs can reduce the gag reflex but still allows patients to vocalize and offer adequate conditions for pharyngeal 
observation during EGD[4].
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